Specialty Chemicals company Rossari Biotech announced Q4FY25 & FY25 results Q4FY25 Financial Highllights: Revenue from operations grew 22.6% to Rs 579.6 crore as compared to Rs 472.7 crore. EBITDA improved by 9.3% to Rs 69.5 crore from Rs 63.6 crore. EBITDA margin at 12.0% as against 13.5%. PAT increased by 0.9% to Rs 34.4 crore from Rs 34.1 crore. EPS (Diluted) stood at Rs 6.21 as against Rs 6.17. FY25 Financial Highllights: Revenue from operations stood at Rs 2,080.3 crore as against Rs 1,830.6 crore, up 13.7%. EBITDA increased by 6.1% to Rs 265.1 crore as against Rs 249.8 crore. EBITDA margin at 12.7% as against 13.6%. PAT higher by 4.4% to Rs 136.4 crore as against Rs 130.7 crore. EPS (Diluted) stood at Rs 24.63 as against Rs 23.62. Edward Menezes, Promoter & Executive Chairman, & Sunil Chari, Promoter & Managing Director, said: “We concluded the year with a steady performance, navigating a soft and evolving operating environment. Revenues grew by ~14% driven by healthy export momentum and resilient volumes across key categories. The HPPC segment remained the primary growth driver, supported by deeper market penetration and strong traction across agrochemicals, personal care, institutional and consumer business. The TSC and AHN segments recorded modest revenue growth, contributing positively to the overall performance. We remain optimistic about their medium-to-long-term potential, supported by ongoing portfolio optimization efforts. Export markets continued to perform well during the year, validating our strategic investments in global partnerships and differentiated solutions. We are also encouraged by the growing momentum in emerging verticals such as institutional cleaning and B2C businesses, which reflect our ability to build scalable, value-added platforms aligned with evolving customer needs. We continue to invest in capacity enhancement to strengthen our growth foundation and are pleased to announce an additional capex of Rs 97 crore for expansions at our subsidiaries, Unitop Chemicals and Tristar Intermediates, along with Rs 95 crore at Rossari Biotech. These projects, expected to be commissioned in a phased manner by Q4 FY26, are aimed at supporting growth across our key chemistries, improving operational efficiency, and enhancing supply reliability. Our previously announced expansion projects are progressing well, with commissioning expected by Q2 FY26. With these capacity additions, we are well-positioned to meet growing demand across end-user industries. Looking ahead, we remain focused on delivering sustainable, profitable growth through sharp execution, customer-centric innovation, and strategic diversification. Supported by a strong balance sheet, an agile business model, and a growing global footprint, we are confident in our ability to maintain healthy growth momentum in the coming years.” Result PDF